High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 17, Issue 8, 2003, Pages 479-482

  Moskovitz, David N ^a   Manoharan, Pooma ^a   Heathcote, E Jenny ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Hepatitis B; Interferon; Nonresponders; Sustained response

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MYALGIA; PRIORITY JOURNAL; TIME;

EID: 0142180162     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/131943     Document Type: Article

References (23)

1. Choo Q-L, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451-5.
2. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
3. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self limiting posttransfusion hepatitis C. Hepatology 1995;21:639-44.
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
5. Hu KQ, Tong MJ. The long-tern outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-6.
6. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
7. Canadian Association for the Study of the Liver. Canadian consensus conference on the management of viral hepatitis. Can J Gastroenterol 2000;14(Suppl B):5B-20B.
8. European Association for the Study of the Liver International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. J Hepatol 1999;30:956-61.
9. Farrell GC. Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know. J Gastroenterol Hepatol 2000;15(Suppl):E126-9.
10. McHutchison JG, Gordon S, Schiff ER, et al. Interferon alpha-2b monotherapy versus interferon alpha-26 plus ribavirin as initial treatment for chronic hepatitis C: Results of a US multicenter randomized controlled study. N Engl J Med 1998;339:1485-92.
11. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
12. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
13. Alton K, Stabinsky Y, Richards R, et al. Production, characterization and biological effects of recombinant DNA derived human IFN-alpha and IFN-gamma analogs. In: De Maeyer E, Schellekens H, eds. The Biology of the Interferon System. Amsterdam: Elsevier, 1983:119-28.
14. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology 1997;26:747-54.
15. Heathcote EJ, Keeffe EB, Lee SS. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
16. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
17. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000;32:630-4.
18. Tabone M, Ercole E, Zaffino C, et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998;30:611-3.
19. Fong TL, Fried MW, Clarke-Platt J. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. Am J Gastroenterol 1999;94:990-3.
20. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-9.
21. Senturk H, Uzunalimoglu O, Batur Y, et al. Long-term efficacy of interferon-α and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci 1997;42:1438-44.
22. Nelson DR, Lauwers GY, Lau JYN, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-60.
23. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term inteferon alfa therapy. Arch Int Med 1987;147:1577-80.